<<looking down the road>>
Then look at this little baby.....consider the following....during the worst economic and market period in our history this company :
Has kicked butt and continued to kick butt growing at a very nice rate. Consider the very low float of I think 11 million shares, of which insider control MOST of.
Consider they are PROFITABLE
Consider they have Mucho Cash in the bank
Consider they are debt free
Consider they own part of a company soon to go public, who's research and technology just cured two people who doctors said had NO CHANCE OF SURVIVAL ( leukemia I believe )
Consider their astounding growth rate.
Consider the fact their market is 99% UNTAPPED.
Do some DD on this company, it's really something, and could see very good growth over the coming years.....and the new company they own a part of....it too, has a great chance of being a good find.....
<<CRYO-CELL Posts All-Time Monthly Sales Record
August 02, 2002 14:02:00 (ET)
CLEARWATER, Fla., Aug 2, 2002 /PRNewswire-FirstCall via COMTEX/ -- CRYO-CELL International, Inc. (CCEL, Trade) announced today that the Company reached record monthly sales with unaudited July 2002 revenues of approximately $638,000.
Highlights for July 2002 include the following:
* Year-to-date 2002 revenues from umbilical cord blood processing and
preservation only were $4.5 million vs. $2.8 million during the first
eight months of 2001, representing a 62% year-over-year increase.
* Total YTD revenues were $4.5 million vs. $3.5 million in 2001,
representing a 28% increase. (2001 revenues included $750,000 from the
sale of a Revenue Sharing Agreement.)
* July 2002 revenues of $638,000 represent a 43% increase over comparable
July 2001 revenues of $446,926 from umbilical cord blood processing and
preservation.
* Year-to-date recurring storage revenue was $700,000 vs. $328,000 during
the same period of 2001, representing a 115% increase.
John V. Hargiss, President and Chief Executive Officer stated, "Â7ly 2002 was the laXeest revenue month in the Company's history, surpassing the prior month's record performance by 6%. The record year-to-date revenue performance has been driven, in part, by the last 4 months of record processing-related revenues and a doubling of storage revenues for previously processed and banked specimens. In addition, inquiries regarding our cord blood processing service reached record levels of nearly 5,000 during July. Actual client enrollments increased to over 1,900, a 5% increase over June levels." Hargiss continued, "We attribute this growing demand to the Company's marketing and referral programs that have created a robust referral base from physicians and other medical caregivers. Moreover, CRYO-CELL's personalized and caring service has created thousands of satisfied clients who in turn have become repeat customers and a steady source of new client referrals."
According to the Company, none of the above figures include license fees from international operations, which are included as other income. The Company's cash position of over $5 million remains strong with no long-term debt.
The Company reported that it had processed and preserved a record number of cord blood specimens, with July units processed exceeding June by over 9%. Total banked specimens have reached approximately 38,000 in the U.S.
CRYO-CELL is a publicly traded company. NASDAQ Symbol ... C C E L. Based in Clearwater, Florida, CRYO-CELL is now the world's largest and fastest growing U-Cord(TM) stem cell banking firm, offering affordable cord blood storage exclusively for the benefit of newborn babies and possibly other members of their family. CRYO-CELL has pioneered America's most affordable U- Cord preservation program. Web site www.cryo-cell.com.
Forward-Looking Statement
Statements wherein the terms "believes," "intends," "projects" or "expects" as used are intended to reflect "forward-looking statements" of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs. Readers should carefully review the risk factors described in other documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any Current Reports on Form 8-K filed by the Company.
MAKE YOUR OPINION COUNT - Click Here
tbutton.prnewswire.com
SOURCE CRYO-CELL International, Inc.
CONTACT: Jill Taymans of CRYO-CELL International, Inc., +1-727-723-0333,
or fax, +1-727-723-0444, or investor.relations@cryo-cell.com |
